Individuals in Taiwan who suffer from migraine were at an increased risk of developing neovascular age-related macular degeneration.
Individuals suffering from migraine have a 20% increased risk of being diagnosed with neovascular age-related macular degeneration (AMD), according to a nationwide population-based study published in Scientific Reports.
AMD is one of the leading causes of blindness and visual impairment worldwide, while prevalence typically rises after age 75. Although previous research has found neovascular AMD is confined to the eye, newer studies have yielded evidence “on the co-occurrence of diseases affecting the eyes, heart and brain due to similar underlying vascular pathology, particularly showing that endothelial dysfunction may play a role,” authors explained.
For example, AMD has been shown to be associated with heart failure and cardiovascular disease; increased high-density lipoprotein cholesterol also increases AMD risk.
Notably, it has been suggested blood vessel pathology, specifically of endothelial cells, could play a causual role in migraine pathogenesis. However, blood vessels involved in migraine causation remains controversial, researchers said. Recent research has also underscored the role of neurovascular mechanisms in migraine.
To investigate a potential link between migraine and neovascular AMD, investigators assessed claims data from patients listed in the Taiwan National Health Insurance (NHI) Research Database (NHIRD).
Between January 2010 and December 2016, a total of 26,209 patients received a first-time diagnosis of neovascular AMD. Of these, 20,333 individuals were included in the final analysis and matched with controls (n = 81,332) from remaining NHIRD beneficiaries.
“We estimated the odds of a previous diagnosis of migraine prior to the index date for cases relative to controls by matching the study patients to ambulatory care claims prior to the index date,” authors explained.
Mean patient age was around 71 years and 5184 sample patients (5.1%) had migraine prior to the index date (1215 patients with AMD [6.1%] and 3969 controls [4.9%; P < .001]).
Analyses revealed:
Inflammatory markers in the eye may be linked to and co-occur with the activation of inflammatory pathways in the heart, potentially accounting for the shared common risk factors of AMD, cardiovascular disease, and stroke, researchers said. Endothelial dysfunction and oxidative stress are also common in AMD and cardiovascular disease, while dysregulation of vascular endothelial growth factors has been observed at migraine attack onset.
However, “the common molecular mechanisms underlying neovascular AMD, cardiovascular disease and migraine remain intriguing and complex, worthy of further investigation,” authors wrote.
The NHIRD does not include information on family history and lifestyle risk factors such as smoking and diet, marking a limitation to the study. Researchers were also unable to assess AMD severity and caution results may not be generalizable to ethnic groups outside of the Han Chinese ethnicity.
“Our study suggests that clinicians should be alert to the potential for neovascular AMD among migraine sufferers and should refer them for periodic fundus examinations by an ophthalmologist,” they concluded.
Reference
Kuang T, Xirasagar S, Kao Y, Ho J, and Lin H. Association of neovascular age-related macular degeneration with migraine. Sci Rep. Published online February 2, 2022. doi:10.1038/s41598-022-05638-5
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More